The use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, the development ...
Made available in DSpace on 2014-12-03T13:11:00Z (GMT). No. of bitstreams: 0 Previous issue date: 2013-11-13Bitstream added on 2014-12-03T13:22:50Z : No. of bitstreams: 1 WOS000327254700167.pdf: 814540 bytes, checksum: e0d75b567b3498a46b360a4289d79ce6 (MD5); Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq); FINEP (CT-BIOTEC-Antic...